4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• 4D Molecular Therapeutics Inc FDMT.OQ reported a quarterly adjusted loss of 98 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -63 cents. The mean expectation of eleven analysts for the quarter was for a loss of 88 cents per share. Wall Street expected results to range from $-1.04 to -78 cents per share.

• Revenue rose 200% to $15.00 thousand from a year ago; analysts expected $374.14 thousand.

• 4D Molecular Therapeutics Inc's reported EPS for the quarter was a loss of 98 cents​.

• The company reported a quarterly loss of $54.66 million.

• 4D Molecular Therapeutics Inc shares had risen by 51.8% this quarter and gained 1.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc is $30.00, about 81.2% above its last closing price of $5.63

This summary was machine generated from LSEG data August 11 at 12:55 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)